Patterned repetitive TMS over the supplementary motor area for Parkinson's bradykinesia
Enhancing rTMS Effects Through a State-Dependent Approach - An Intervention for Bradykinesia in Parkinson's Disease
This trial will try patterned repetitive transcranial magnetic stimulation over the supplementary motor area to reduce slowness of movement in people with Parkinson's disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 27 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Danish Research Centre for Magnetic Resonance Academic / other |
| Locations | 1 site (Hvidovre) |
| Trial ID | NCT07397377 on ClinicalTrials.gov |
What this trial studies
The trial delivers patterned repetitive transcranial magnetic stimulation (prTMS) targeted to the supplementary motor area (SMA) and compares active stimulation with a sham procedure. Participants with clinically established or probable Parkinson's disease who are stable on antiparkinsonian medication will receive sessions of either active or sham prTMS, with motor function measured before and after the intervention. The study excludes people with epilepsy risk, certain psychiatric medications, MRI or TMS contraindications, and pregnant participants. Results will focus on changes in bradykinesia severity and related motor measures.
Who should consider this trial
Good fit: Adults (18+) with clinically established or probable Parkinson's disease, on stable antiparkinsonian medication, able to undergo MRI and TMS, and willing to give informed consent are ideal candidates.
Not a fit: People with contraindications to TMS or MRI, a history or family risk of seizures, current use of excluded psychiatric or GABAergic medications, or who are pregnant are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, this could reduce bradykinesia symptoms with a noninvasive treatment and potentially delay or reduce the need for invasive options like deep brain stimulation.
How similar studies have performed: Noninvasive TMS approaches have shown promise in small studies for motor symptoms, but patterned rTMS over the SMA remains relatively novel and not yet widely proven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Above 18 years of age. Clinically established or probable Parkinson's Disease (PD), according to the Movement Disorder Society. Clinical Diagnostic Criteria for PD. Stable antiparkinsonian medicine for at least four weeks. Signed informed consent. Exclusion Criteria: Psychiatric disorders. Current use of antipsychotic medication, Donepezil, or GABAergic agents (e.g., pregabalin, gabapentin). Frequent benzodiazepine or opioid use defined as more than once per week on a regular basis. History of neurological disease other than PD. Past or present mental illness. History of epilepsy/conditions associated with increased risk of seizure induction through transcranial magnetic stimulation (TMS). Close relatives suffering from epilepsy/conditions associated with increased risk of seizures. Contraindications for magnetic resonance imaging (MRI) Contraindications for TMS Female participants of childbearing age must not be pregnant and must use contraception during the trial. Refuse to be informed about new health-related information and accidental health-related findings that might appear through participation in the study.
Where this trial is running
Hvidovre
- Drcmr — Hvidovre, Denmark (Recruiting)
Study contacts
- Study coordinator: Ann-Charlot Rughaven, M.Sc.
- Email: ann-charlot.rughaven@regionh.dk
- Phone: +4521123531
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.